Clinical

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

A study led by Meng-Han Tsai, PhD, found that men and racial and ethnic minority patients with early-onset CRC in urban areas face a higher CVD death risk.

This new analysis highlights zanubrutinib’s survival benefits and lower cardiac toxicity in chronic lymphocytic leukemia.

Rising urine albumin signals higher heart and kidney risk; learn how better screening, EHR prompts, and new therapies can transform CKD care.

Ontada finds that EHR-based education boosts NCCN guideline-concordant care for patients with HER2-low metastatic cancer, raising targeted treatment use among providers who took part in the education activities.

Discover the stroke care team—from primary care to rehab—plus proven prevention steps and the high stakes of recurrent stroke.

Stroke subtypes vary widely, but prevention is clear: control blood pressure, diabetes, cholesterol, exercise, quit smoking, and cut disability costs.

Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about rural disparities.

James F. Howard, MD, discusses the significance of the FDA expanding the label for efgartigimod in patients with generalized myasthenia gravis (gMG).

Mark Metersky, MD, discussed heterogeneity, pathogens, and precision approaches in community-acquired pneumonia care.

This review will appear in the June issue of Evidence-Based Oncology.

Eli Lilly's triple agonist achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks, matching bariatric surgery levels.

A retrospective analysis comparing 3-year psoriatic arthritis incidence across immunomodulatory classes finds an emerging signal favoring IL-23 pathway agents—a finding with meaningful implications for treatment selection in patients at risk for joint disease.

Chronic hand eczema care is marked by high costs, fragmented treatment, and a clinical overreliance on steroids.

The panelist explored the following critical questions: What systems-level strategies can improve coverage readiness for new metabolic dysfunction-associated steatohepatitis (MASH) treatments? What system-wide transformations are necessary to sustain scalable, multidisciplinary MASH care? What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

In this episode, 'System-Level Barriers and Evidence Gaps in the Adoption of Emerging MASH Therapies,' the expert hepatologist explored the following questions: What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Welcome back to another AJMC Insights series. In this episode titled, 'The Financial and Clinical Cost of Delayed MASH Detection and Fragmented Care', Dr. Jaideep Behari led the conversation about the following questions: The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Kirk Campbell, MD, discusses why FSGS is traditionally difficult to treat, the significance of the sparsentan approval, and future access needs.

Financial toxicity independently predicts a lower quality of life for patients with HS, with greater disease severity and biologic use driving the strain.

An investigational coronary IVL catheter achieved high procedural success and favorable safety outcomes in patients with severely calcified CAD.

New data examine switching biologics in severe asthma and inhaled treprostinil's effect on lung function in idiopathic pulmonary fibrosis (IPF).

Poster data show the efficacy of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis.

Kirk Campbell, MD, sees sparsentan as the beginning of a new treatment era for FSGS, a condition that has lacked approved therapies until now.

After vitiligo diagnosis, many patients remain untreated and switch quickly between therapies, according to new data on treatment patterns.

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.